Ivermectin Pill: Mosquito Killer, Malaria Reduction Study
Ivermectin Shows Promise in Reducing Malaria Transmission in African Trials
Table of Contents
New research from the Unitaid-funded BOHEMIA project indicates that ivermectin, administered through Mass Drug Administration (MDA), could be a notable new tool in the fight against malaria, notably in high-burden regions of Africa.
Promising Results from BOHEMIA Project Trials
The BOHEMIA project, which stands for Broad One Health Endectocide-based Malaria Intervention in Africa, conducted two large-scale MDA trials in Kwale County, Kenya, and Mopeia district, Mozambique. These trials aimed too assess the safety and efficacy of a single monthly dose of ivermectin (400 mcg/kg) given for three consecutive months at the onset of the rainy season, a critical period for malaria transmission.
Ivermectin’s Impact on malaria Incidence
In Kwale County, Kenya, the trial focused on children aged 5-15. The results were encouraging, with children who received ivermectin experiencing a 26% reduction in malaria infection incidence compared to those who received albendazole, the control drug. This significant reduction highlights ivermectin’s potential to disrupt malaria transmission cycles.
The Kenyan trial involved over 20,000 participants and administered more than 56,000 treatments. The data demonstrated that ivermectin was particularly effective in reducing malaria infection rates among children residing further from cluster borders or in areas where drug distribution was more efficient, suggesting that consistent and widespread administration is key to maximizing its impact.
Safety and Future Potential
Crucially, the safety profile of ivermectin in these trials was favorable. Researchers reported no severe drug-related adverse events. The side effects observed were mild and transient, consistent with those previously documented in campaigns against neglected tropical diseases where ivermectin has been widely used.
“We are thrilled with these results,” stated Carlos Chaccour, co-principal investigator of the BOHEMIA project and an ISGlobal researcher at the time of the study. “Ivermectin has shown great promise in reducing malaria transmission and could complement existing control measures. With continued research, ivermectin MDA could become an effective tool for malaria control and even contribute to elimination efforts.” Chaccour, now a researcher at the Navarra Center for international Progress at the university of Navarra, emphasized the long-term potential of this intervention.
Alignment with Global Health Strategies
The findings from the BOHEMIA project align with the World Health association’s (WHO) criteria for new vector control tools. Joseph Mwangangi from the KEMRI-Wellcome Trust Research Program commented, “These results suggest that ivermectin MDA could be a valuable complementary strategy for malaria control, particularly in areas where mosquito resistance to insecticides is a growing concern.”
Marta Maia, BOHEMIA’s lead entomologist from the University of Oxford, added, “The findings suggest that ivermectin MDA could be a valuable complementary strategy for malaria control, particularly in areas where mosquito resistance to insecticides is a growing concern.”
The study is part of a broader global initiative to evaluate ivermectin’s role in malaria control. The WHO vector control advisory group has reviewed the findings, recognizing the demonstrated impact and recommending further research. These results have also been shared with national health authorities as they consider the potential inclusion of ivermectin in their malaria control programs.